AU2019275607A1 — Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
Assigned to Global Blood Therapeutics Inc · Expires 2020-01-02 · 6y expired
What this patent protects
[0242] Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of haemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders media…
USPTO Abstract
[0242] Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of haemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
Drugs covered by this patent
- Oxbryta (voxelotor) · Global Blood Theraps
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.